| p95HER2–T cell bispecific antibody for breast cancer treatment IR Ruiz, R Vicario, B Morancho, CB Morales, EJ Arenas, S Herter, ... Science translational medicine 10 (461), eaat1445, 2018 | 64 | 2018 |
| Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation EJ Arenas, A Martínez-Sabadell, IR Ruiz, MR Alonso, M Escorihuela, ... Nature communications 12 (1), 1-13, 2021 | 33 | 2021 |
| LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer I Pérez-Núñez, C Rozalén, JÁ Palomeque, I Sangrador, M Dalmau, ... Nature Cancer, 1-16, 2022 | 27 | 2022 |
| Novel principles of gamma-retroviral insertional transcription activation in murine leukemia virus-induced end-stage tumors M Sokol, M Wabl, IR Ruiz, FS Pedersen Retrovirology 11 (1), 36, 2014 | 24 | 2014 |
| Identification of novel mechanisms of resistance against the redirection of T-cell effector function for cancer therapy EJA Lahuerta, A Martínez-Sabadell, IR Ruiz, B Morancho, M Román, ... Cancer Research 80 (16 Supplement), 5570-5570, 2020 | | 2020 |
| Abstract LB-292: p95HER2-T cell bispecific antibody for breast cancer treatment R Vicario, IR Ruiz, B Morancho, CB Morales, S Herter, ... Cancer Research 78 (13 Supplement), LB-292-LB-292, 2018 | | 2018 |
